Literature DB >> 34538096

Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association.

Michael E Hall, Jordana B Cohen, Jamy D Ard, Brent M Egan, John E Hall, Carl J Lavie, Jun Ma, Chiadi E Ndumele, Philip R Schauer, Daichi Shimbo.   

Abstract

Hypertension is a major risk factor for cardiovascular and renal diseases in the United States and worldwide. Obesity accounts for much of the risk for primary hypertension through several mechanisms, including neurohormonal activation, inflammation, and kidney dysfunction. As the prevalence of obesity continues to increase, hypertension and associated cardiorenal diseases will also increase unless more effective strategies to prevent and treat obesity are developed. Lifestyle modification, including diet, reduced sedentariness, and increased physical activity, is usually recommended for patients with obesity; however, the long-term success of these strategies for reducing adiposity, maintaining weight loss, and reducing blood pressure has been limited. Effective pharmacotherapeutic and procedural strategies, including metabolic surgeries, are additional options to treat obesity and prevent or attenuate obesity hypertension, target organ damage, and subsequent disease. Medications can be useful for short- and long-term obesity treatment; however, prescription of these drugs is limited. Metabolic surgery is effective for producing sustained weight loss and for treating hypertension and metabolic disorders in many patients with severe obesity. Unanswered questions remain related to the mechanisms of obesity-related diseases, long-term efficacy of different treatment and prevention strategies, and timing of these interventions to prevent obesity and hypertension-mediated target organ damage. Further investigation, including randomized controlled trials, is essential to addressing these questions, and emphasis should be placed on the prevention of obesity to reduce the burden of hypertensive cardiovascular and kidney diseases and subsequent mortality.

Entities:  

Keywords:  AHA Scientific Statements; blood pressure; metabolic surgery; obesity

Mesh:

Substances:

Year:  2021        PMID: 34538096     DOI: 10.1161/HYP.0000000000000202

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  12 in total

1.  BMI and blood pressure control among United States adults with hypertension.

Authors:  Kathryn Foti; Shakia T Hardy; Alex R Chang; Elizabeth Selvin; Josef Coresh; Paul Muntner
Journal:  J Hypertens       Date:  2022-04-01       Impact factor: 4.844

Review 2.  Cardiovascular risk in patients receiving antihypertensive drug treatment from the perspective of endothelial function.

Authors:  Tatsuya Maruhashi; Yukihito Higashi
Journal:  Hypertens Res       Date:  2022-05-20       Impact factor: 5.528

3.  Huoxue Qianyang Qutan Recipe Protects against Early Renal Damage Induced by Obesity-Related Hypertension via the SIRT1/NF-κB/IL-6 Pathway: Integrating Network Pharmacology and Experimental Validation-Based Strategy.

Authors:  Mingzhu Wang; Jianhua Li; Mingtai Gui; Bo Lu; Lei Yao; Xunjie Zhou; Moyi Shi; Liang Hu; Deyu Fu
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-27       Impact factor: 2.650

4.  Effects of Arterial Stiffness and Carotid Intima-Media Thickness Progression on the Risk of Overweight/Obesity and Elevated Blood Pressure/Hypertension: a Cross-Lagged Cohort Study.

Authors:  Andrew O Agbaje; Alan R Barker; Tomi-Pekka Tuomainen
Journal:  Hypertension       Date:  2021-11-17       Impact factor: 10.190

5.  Prevalence of Prehypertension and Associated Cardiovascular Risk Profiles among Adults in Peru: Findings from a Nationwide Population-Based Study.

Authors:  Akram Hernández-Vásquez; Rodrigo Vargas-Fernández
Journal:  Int J Environ Res Public Health       Date:  2022-06-27       Impact factor: 4.614

6.  Association between Legume Consumption and Risk of Hypertension in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk Cohort.

Authors:  Michael Hartley; Claire L Fyfe; Nicholas J Wareham; Kay-Tee Khaw; Alexandra M Johnstone; Phyo K Myint
Journal:  Nutrients       Date:  2022-08-16       Impact factor: 6.706

7.  Early Pandemic Improvements in Diet Quality Are Associated with Increased Physical Activity and Weight Loss in US Adults.

Authors:  Corinne E Gautreaux; Kristen S Smith; Luke Dolan; Michael B Marlin; Michael W Greene; Josh R Novak; Andrew D Frugé
Journal:  Int J Environ Res Public Health       Date:  2022-07-07       Impact factor: 4.614

8.  Metabolic syndrome - a new definition and management guidelines: A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, "Club 30" Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons.

Authors:  Piotr Dobrowolski; Aleksander Prejbisz; Alina Kuryłowicz; Alicja Baska; Paweł Burchardt; Krzysztof Chlebus; Grzegorz Dzida; Piotr Jankowski; Jerzy Jaroszewicz; Paweł Jaworski; Karol Kamiński; Agnieszka Kapłon-Cieślicka; Marek Klocek; Michał Kukla; Artur Mamcarz; Agnieszka Mastalerz-Migas; Krzysztof Narkiewicz; Lucyna Ostrowska; Daniel Śliż; Wiesław Tarnowski; Jacek Wolf; Mariusz Wyleżoł; Tomasz Zdrojewski; Maciej Banach; Andrzej Januszewicz; Paweł Bogdański
Journal:  Arch Med Sci       Date:  2022-08-30       Impact factor: 3.707

9.  Mediating role of body composition and insulin resistance on the association of arterial stiffness with blood pressure among adolescents: The ALSPAC study.

Authors:  Andrew O Agbaje
Journal:  Front Cardiovasc Med       Date:  2022-09-02

Review 10.  Chrononutrition in Cardiometabolic Health.

Authors:  Vasiliki Katsi; Ilias P Papakonstantinou; Stergios Soulaidopoulos; Niki Katsiki; Konstantinos Tsioufis
Journal:  J Clin Med       Date:  2022-01-07       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.